Vertical farms, woke AI, and 23andMe made our annual list of failed tech. From chatbots dishing out illegal advice to dodgy ...

From cloud chaos to clarity.” In this episode, AT&T’s Erian Laperi, Kristina Sutton, and Dan Wagner discuss transforming one ...

Genetic testing firm 23andMe is reportedly considering the sale of its telehealth division, Lemonaid Health, according to ...

One reason for this is because the answer is that it is impossible to know for sure. Your data is at risk, but the extent to which it is at risk is unclear. But there are facts, law and precedent ...

The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its telehealth offering, Business Insider has learned. 23andMe has been testing the waters for a buyer ...

23andMe CEO Anne Wojcicki sounded optimistic about the company's future during an earnings call in February last year. She said the biotech company, which offers direct-to-consumer genetic testing ...

The struggling health company bought the virtual-care startup Lemonaid in 2021 for $400 million. 23andMe's stock plummeted after a 2023 data breach exposed millions of customer accounts.

23andMe faced major hurdles in 2024, including a $30 million settlement related to compromised data. 23andMe is now restructuring its business operations to reduce costs and streamline operations.

23andMe has been exploring a possible sale of its telehealth business, Business Insider has learned. The struggling health company bought the virtual-care startup Lemonaid in 2021 for $400 million.